Location: Home > Products > Our Products > RNAi 實驗細胞分析 > RNAi 轉染試劑細胞轉染 > TransIT-X2®

找出您實驗的最佳轉染試劑

友善列印TransIT-X2®

  • 採用創新非脂質體聚合物配方 (non-liposomal polymer),轉染效率更佳,並能大幅降低細胞毒殺性。
  • 對於 plasmid DNA 及 siRNA / miRNA 皆具有高轉染效率,可以進行 Co-transfection 實驗。
  • 不含任何動物來源成份,可安心使用於 "animal origin-free" 實驗。

 

         
TransIT-X2® achieves better/comparable DNA delivery to Lipofectamine® 2000 in 36/41 cell types tested. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect plasmid DNA encoding luciferase into 41 different cell types at three reagent-to-DNA ratios. Luciferase expression was compared at 24 hours post-transfection using a standard luciferase assay. Head-to-head comparisons at optimized ratios illustrate superior or equal luciferase expression using TransIT-X2® in 36 of 41 cell types; 17 cell types that had expression levels 2-fold higher are denoted with ‡.
                  
Functional Co-delivery of Plasmid DNA and siRNA using TransIT-X2® Dynamic Delivery System. TransIT-X2® Dynamic Delivery System was used to transfect plasmid Cy®5 labeled DNA encoding nuclear YFP and Cy®3 labeled siRNA into HeLa cells. Transfection was performed in a 6-well plates with Poly-L-Lysine (PLL) coated coverslips using 4 µl of TransIT-X2® to deliver 2 µg of DNA and 25 nM siRNA (2:1 reagent:DNA ratio). Actin cytoskeleton was stained using Alexa Fluor® 350 Phalloidin. Image (63X) were captured at 24 hours post-transfection using a Nikon A1R confocal microscope. Image key: yellow (nuclear YFP), blue (Cy5 labeled DNA), red (Cy3 labeled siRNA), green (actin cytoskeleton).
           
TransIT-X2® Dynamic Delivery System Achieves Higher Knockdown than Lipofectamine® 2000. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect siRNA targeting endogenous proteins - GAPDH, aha1 or non-targeting control in normal human dermal fibroblasts (NHDF). Cells were transfected in a 6-well plate using 4 µl of TransIT-X2® or 6 µl of Lipofectamine® 2000 and 25 nM siRNA according to each manufacturer's protocol. The amount of GAPDH or aha1 mRNA was measured relative to 18s rRNA levels using qRT-PCR and then normalized to the mRNA levels of the non-targeting control, 48 hours post-transfection. Error bars represent the standard deviation of triplicate wells.
           
Effective miRNA Delivery using TransIT-X2® Dynamic Delivery System Yields Decreased Levels of PTK9 mRNA. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect Pre-miR® hsa-miR-1 miRNA Precursor or mirVana® miRNA mimic, miR-1, both known to decrease PTK9 mRNA levels. A Pre-miR negative control was transfected to assess baseline mRNA levels. T47D cells were transfected in a 12-well plate using 3 µl of TransIT-X2® or Lipofectamine® 2000 and 50 nM miRNA according to each manufacturer's protocol. The amount of PTK9 mRNA was measured relative to 18s rRNA levels using qRT-PCR and then normalized to the mRNA levels of the negative control, 48 hours post-transfection. Error bars represent the standard deviation of triplicate wells.

 

訂購資訊

Product Pack Size Cat. No.
TransIT-X2® Dynamic Delivery System 0.3 ml MR-MIR6003
0.75 ml MR-MIR6004
1.5 ml MR-MIR6000
5 x 1.5 ml MR-MIR6005
10 x 1.5 ml MR-MIR6006

 

首頁關於伯森最新消息 產品介紹代客服務聯絡我們 站內搜尋
© BLOSSOM BIOTECHNOLOGIES INC. All rights reserved.